Importantly, in line with data on experimental arthritis [25], APRIL-Tg mice do not show the severe adverse effects associated with BAFF receptor signaling (the other ligand for BCMA and TACI) [7,17], exhibiting significantly lower percentages of the atherogenic B2 lymphocyte subset. Here, TNFRSF17 is linked to arthritic joint disease.